Discounted Cash Flow (DCF) Analysis Levered
AVITA Medical, Inc. (RCEL)
$13.6
+0.07 (+0.52%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.88 | 5.40 | 14.26 | 29.23 | 34.42 | 103.24 | 309.67 | 928.82 | 2,785.91 | 8,356.10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -12.03 | -19.25 | -22.75 | -25.90 | -19.09 | -418.32 | -1,254.70 | -3,763.37 | -11,287.88 | -33,856.99 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.37 | -1.26 | -0.85 | -1.17 | -0.45 | -15.73 | -47.17 | -141.48 | -424.35 | -1,272.80 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -12.39 | -20.51 | -23.59 | -27.08 | -19.54 | -434.04 | -1,301.87 | -3,904.84 | -11,712.23 | -35,129.79 |
Weighted Average Cost Of Capital
| Share price | $ 13.6 |
|---|---|
| Beta | 0.969 |
| Diluted Shares Outstanding | 22.67 |
| Cost of Debt | |
| Tax Rate | -0.14 |
| After-tax Cost of Debt | 5.23% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.140 |
| Total Debt | 0.31 |
| Total Equity | 308.37 |
| Total Capital | 308.68 |
| Debt Weighting | 0.10 |
| Equity Weighting | 99.90 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.88 | 5.40 | 14.26 | 29.23 | 34.42 | 103.24 | 309.67 | 928.82 | 2,785.91 | 8,356.10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.03 | -19.25 | -22.75 | -25.90 | -19.09 | -418.32 | -1,254.70 | -3,763.37 | -11,287.88 | -33,856.99 |
| Capital Expenditure | -0.37 | -1.26 | -0.85 | -1.17 | -0.45 | -15.73 | -47.17 | -141.48 | -424.35 | -1,272.80 |
| Free Cash Flow | -12.39 | -20.51 | -23.59 | -27.08 | -19.54 | -434.04 | -1,301.87 | -3,904.84 | -11,712.23 | -35,129.79 |
| WACC | ||||||||||
| PV LFCF | -401.37 | -1,113.26 | -3,087.77 | -8,564.34 | -23,754.38 | |||||
| SUM PV LFCF | -36,921.12 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 8.14 |
| Free cash flow (t + 1) | -35,832.39 |
| Terminal Value | -583,589.37 |
| Present Value of Terminal Value | -394,616.78 |
Intrinsic Value
| Enterprise Value | -431,537.90 |
|---|---|
| Net Debt | -17.86 |
| Equity Value | -431,520.04 |
| Shares Outstanding | 22.67 |
| Equity Value Per Share | -19,031.23 |